ALKS vs. MDGL, FOLD, IONS, GERN, AGIO, LGND, DVAX, PCRX, MNKD, and IRWD
Should you be buying Alkermes stock or one of its competitors? The main competitors of Alkermes include Madrigal Pharmaceuticals (MDGL), Amicus Therapeutics (FOLD), Ionis Pharmaceuticals (IONS), Geron (GERN), Agios Pharmaceuticals (AGIO), Ligand Pharmaceuticals (LGND), Dynavax Technologies (DVAX), Pacira BioSciences (PCRX), MannKind (MNKD), and Ironwood Pharmaceuticals (IRWD). These companies are all part of the "pharmaceutical preparations" industry.
Alkermes (NASDAQ:ALKS) and Madrigal Pharmaceuticals (NASDAQ:MDGL) are both mid-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, community ranking, dividends, profitability, valuation, risk, media sentiment and analyst recommendations.
Alkermes received 235 more outperform votes than Madrigal Pharmaceuticals when rated by MarketBeat users. Likewise, 70.69% of users gave Alkermes an outperform vote while only 68.60% of users gave Madrigal Pharmaceuticals an outperform vote.
95.2% of Alkermes shares are owned by institutional investors. Comparatively, 98.5% of Madrigal Pharmaceuticals shares are owned by institutional investors. 4.9% of Alkermes shares are owned by insiders. Comparatively, 23.9% of Madrigal Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
In the previous week, Madrigal Pharmaceuticals had 21 more articles in the media than Alkermes. MarketBeat recorded 29 mentions for Madrigal Pharmaceuticals and 8 mentions for Alkermes. Alkermes' average media sentiment score of 1.49 beat Madrigal Pharmaceuticals' score of -0.02 indicating that Alkermes is being referred to more favorably in the media.
Alkermes has higher revenue and earnings than Madrigal Pharmaceuticals. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks.
Alkermes currently has a consensus target price of $35.38, indicating a potential upside of 44.45%. Madrigal Pharmaceuticals has a consensus target price of $345.09, indicating a potential upside of 63.57%. Given Madrigal Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Madrigal Pharmaceuticals is more favorable than Alkermes.
Alkermes has a net margin of 25.17% compared to Madrigal Pharmaceuticals' net margin of 0.00%. Alkermes' return on equity of 20.31% beat Madrigal Pharmaceuticals' return on equity.
Alkermes has a beta of 0.61, indicating that its stock price is 39% less volatile than the S&P 500. Comparatively, Madrigal Pharmaceuticals has a beta of -0.33, indicating that its stock price is 133% less volatile than the S&P 500.
Summary
Alkermes beats Madrigal Pharmaceuticals on 11 of the 17 factors compared between the two stocks.
Get Alkermes News Delivered to You Automatically
Sign up to receive the latest news and ratings for ALKS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ALKS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Alkermes Competitors List
Related Companies and Tools
